Email this article Russian multicenter retrospective study: preliminary data concerning clinical and molecular genetic characteristics in long-term responders to erlotinib
- Authors: Smolin AV1, Gorbacheva AV2
-
Affiliations:
- ФГКУ Главный военный клинический госпиталь им. Н.Н.Бурденко Минобороны России, Москва
- ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
- Issue: Vol 16, No 3 (2014)
- Pages: 81-86
- Section: Articles
- URL: https://bakhtiniada.ru/1815-1434/article/view/26979
- ID: 26979
Cite item
Full Text
Abstract
Background. A key challenge in the treatment of advanced non-small-cell lung cancer (NSCLC) is improving outcomes for patients infirst, second line and maintenance therapy. We analyzed group of patients with progression free survival 6 month in order to elicit predic-tors of long response to the therapy with erlotinib.Methods. Between 2005 and 2013, we collect demographic data about 69 patients with NSCLC with PFS more than 6 month. In first linehave received 27 pts, second line - 36 pts and maintenance therapy - 6 pts. In most cases, data about mutation of EGFR was available.Results. We found possible correlation between level of response and duration of PFS. Duration of PFS in group with complete responsewas - 14,9 month, partial response - 12,9 month, stable disease - 12 month. Cohort of patients with the best response and longest PFSconsist of those with EGFR mutations, women and never or light smokers. We found 6 patients without EGFR mutation, in 5 of them thebest response was durable stable disease and in one - partial response.Conclusion. There are data supporting strong correlation between EGFR mutation status and objective response and duration of PFS inpatients treated with erlotinib. Patient without EGFR mutation have a real chance to reach long lasting stable disease in maintenance andsecond line therapy. Simple clinical characteristic, such as smoking status, gender and tumor histology can be used for selection patientsfor therapy with erlotinib.
Full Text
##article.viewOnOriginalSite##About the authors
A V Smolin
ФГКУ Главный военный клинический госпиталь им. Н.Н.Бурденко Минобороны России, Москваканд. мед. наук, нач. радиологического центра
A V Gorbacheva
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава Россииканд. мед. наук, доц. каф. факультетской хирургии
References
- Morgensztern D, Waqar S, Subramanian J et al. Improving Survival for Stage IV Non - small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Survey from 1990 to 2005. J Thor Oncol 2009; 4: 1524-9.
- Shigematsu H, Lin L, Takahashi T et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. JNCI J Nat Cancer Inst 2005; 97 (5): 339-46.
- Nguyen K.-S.H, Kobayashi S et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non - small - cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10 (4): 281-9.
- Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first - line treatment for European patients with advanced EGFR mutation - positive non - small - cell lung cancer (EURTAC): a multicentre, open - label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
- Gridelli C, Ciardiello R, Feld R et al. International multicenter randomized phase III study of first - line erlotinib (E) followed by second - line cisplatin plus gemcitabine (CG) versus first - line CG followed by second - line E in advanced non - small cell lung cancer (aNSCLC): The TORCH trial (abstract 7508). J Clin Oncol 2010; 28: 15s.
- Zhou C, Wu Y, Chen G et al. Erlotinib vs chemotherapy as first - line treatment for patients with advanced EGFR mutation - positive non - small - cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open - label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
- Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non - small - cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG 3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11 (2): 121-8.
- Paz-Ares L, Soulieres D, Moecks J et al. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation - positive NSCLC.J Cell Mol Med 2014; 18 (8): 1519-39.
- Lee S, Khan I, Upadhyay S et al. First - line erlotinib in patients with advanced non - small - cell lung cancer unsuitable for chemotherapy (TOPICAL): a double - blind, placebo - controlled, phase 3 trial. Lancet Oncol 2012; 13 (11): 1161-70.
- Cappuzzo F, Ciuleanu T, Stelmakh L. On behalf of the SATURN investigators. Erlotinib as maintenance treatment in advanced non - small - cell lung cancer: a multicentre, randomized, placebo - controlled phase 3 study. Lancet Oncol 2010; 11: 521-9.
- Brugger W, Triller N, Blasinska-Morawiec M et al. Biomarker analyses from the phase III placebo - controlled SATURN study of maintenance erlotinib following first - line chemotherapy for advanced NSCLC. J Clin Oncol 2009; 27: 411s.
- Смолин А.В., Борисов В.И., Орлов С.В. и др. Результаты российского многоцентрового исследования по изучению возможности использования клинических предикторов для отбора больных немелкоклеточным раком легкого на терапию эрлотинибом. Соврем. онкол. 2011; 4: 26-32.
Supplementary files
